ZLAB Zai Lab Limited

+0.27  (+1%)
Previous Close 33.46
Open 33.68
Price To Book 7.84
Market Cap 2,232,893,653
Shares 66,199,041
Volume 357,215
Short Ratio
Av. Daily Volume 207,733

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 dosing initiated - noted June 29. 2018.
ZL-2306 (niraparib)
First-line maintenance therapy for platinum-responsive ovarian cancer
China NDA filing announced December 12, 2018.
ZL-2306 (niraparib)
Recurrent platinum-sensitive ovarian cancer
Phase 3 data met PFS primary endpoint - August 13, 2019. Secondary ORR endpoint not achieved. NDA filing due 1Q 2020.
Ripretinib DCC-2618 - INVICTUS
Gastrointestinal Stromal Tumors (GIST) - fourth-line
Phase 3 futility analysis due 1H 2020.
FPA144 + chemo (FIGHT)
Gastric and gastro-esophageal junction cancer
Phase 3 data released July 15, 2019 met primary endpoint.
Niraparib - PRIMA
First-line ovarian cancer
Second interim overall survival analysis and BLA filing due 4Q 2019.
Margetuximab SOPHIA study
Metastatic breast cancer
Phase 2 data due 4Q 2019.
Urinary tract infections
Phase 3 top-line data due 2H 2020.
Acinetobacter baumannii infections
Phase 2 data due 4Q 2019.
Complicated urinary tract infections (cUTI) / acute pyelonephritis

Latest News

  1. China National Medical Products Administration Grants Innovative Medical Device Designation for Optune® in China
  2. Here is What Hedge Funds Think About Zai Lab Limited (ZLAB)
  3. Incyte enters license pact with Zai Lab to commercialize its cancer treatment in Greater China
  4. Incyte and Zai Lab Announce Collaboration and License Agreement for INCMGA0012 in Greater China
  5. Zai Lab Announces Approval to Commercialize ZEJULA (Niraparib) in Macau for Patients with Relapsed Ovarian Cancer
  6. Do Insiders Own Lots Of Shares In Zai Lab Limited (NASDAQ:ZLAB)?
  7. Deciphera Pharmaceuticals, Inc. and Zai Lab Limited Announce an Exclusive License Agreement for Ripretinib in Greater China
  8. Zai Lab Appoints Valeria Fantin, Ph.D., as Chief Scientific Officer
  9. Zai Lab Announces Presentations at June Conferences
  10. Zai Lab Announces CTA Approval to Initiate a Phase 3 Clinical Trial of ETX2514SUL for the Treatment of Carbapenem-Resistant Acinetobacter Infections
  11. Zai Lab Announces Participation at Upcoming May Conferences
  12. Here’s What Hedge Funds Think About Zai Lab Limited (ZLAB)
  13. Zai Lab Announces Pricing of Public Offering of American Depositary Shares
  14. 3 Top Chinese Stocks to Watch in May
  15. Zai Lab Announces Proposed Public Offering of American Depositary Shares
  16. Zai Lab to Host Analyst & Investor Day on April 30, 2019